Cost-utility of early versus delayed treatment with interferon beta-1b in clinically isolated syndrome (CIS) from a United States (US) payer perspective

Authors
Category Systematic review
JournalValue in Health
Year 2017
This article has no abstract
Epistemonikos ID: ab94bfed611b2efff72e212a2da2f8dbaac4b35c
First added on: Feb 08, 2025